Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Sidley says it reviewed the narrowed Medicare Part B GLOBE pricing rule
Sidley said it published an analysis of the final GLOBE drug pricing rule, which it said substantially narrows the proposed mandatory Medicare Part B model. The firm said new product exclusions and planned waivers for GENEROUS participants reduce the model’s reach, while its first performance year now begins April 1, 2027.
Key points
- Sidley said the final rule excludes orphan-only drugs, cell and gene therapies, and plasma-derived products.Sidley
- The firm said CMS estimates four manufacturers would remain in the model.Sidley
- Sidley said CMS reduced estimated annualized Medicare savings from about $2.3 billion to about $80 million.Sidley
- The firm said the five-year performance period ends March 31, 2032, followed by two years of invoicing and reconciliation.Sidley